Characterising long COVID: a living systematic review.
COVID-19
public health
systematic review
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
17
02
2021
accepted:
19
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
1
10
2021
Statut:
ppublish
Résumé
While it is now apparent clinical sequelae (long COVID) may persist after acute COVID-19, their nature, frequency and aetiology are poorly characterised. This study aims to regularly synthesise evidence on long COVID characteristics, to help inform clinical management, rehabilitation strategies and interventional studies to improve long-term outcomes. A living systematic review. Medline, CINAHL (EBSCO), Global Health (Ovid), WHO Global Research on COVID-19 database, LitCovid and Google Scholar were searched till 17 March 2021. Studies including at least 100 people with confirmed or clinically suspected COVID-19 at 12 weeks or more post onset were included. Risk of bias was assessed using the tool produced by Hoy A total of 39 studies were included: 32 cohort, 6 cross-sectional and 1 case-control. Most showed high or moderate risk of bias. None were set in low-income countries and few included children. Studies reported on 10 951 people (48% female) in 12 countries. Most included previously hospitalised people (78%, 8520/10 951). The longest mean follow-up time was 221.7 (SD: 10.9) days post COVID-19 onset. Over 60 physical and psychological signs and symptoms with wide prevalence were reported, most commonly weakness (41%; 95% CI 25% to 59%), general malaise (33%; 95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%) and breathlessness (25%; 95% CI 18% to 34%). 37% (95% CI 18% to 60%) of patients reported reduced quality of life; 26% (10/39) of studies presented evidence of reduced pulmonary function. Long COVID is a complex condition with prolonged heterogeneous symptoms. The nature of studies precludes a precise case definition or risk evaluation. There is an urgent need for prospective, robust, standardised, controlled studies into aetiology, risk factors and biomarkers to characterise long COVID in different at-risk populations and settings. CRD42020211131.
Sections du résumé
BACKGROUND
While it is now apparent clinical sequelae (long COVID) may persist after acute COVID-19, their nature, frequency and aetiology are poorly characterised. This study aims to regularly synthesise evidence on long COVID characteristics, to help inform clinical management, rehabilitation strategies and interventional studies to improve long-term outcomes.
METHODS
A living systematic review. Medline, CINAHL (EBSCO), Global Health (Ovid), WHO Global Research on COVID-19 database, LitCovid and Google Scholar were searched till 17 March 2021. Studies including at least 100 people with confirmed or clinically suspected COVID-19 at 12 weeks or more post onset were included. Risk of bias was assessed using the tool produced by Hoy
RESULTS
A total of 39 studies were included: 32 cohort, 6 cross-sectional and 1 case-control. Most showed high or moderate risk of bias. None were set in low-income countries and few included children. Studies reported on 10 951 people (48% female) in 12 countries. Most included previously hospitalised people (78%, 8520/10 951). The longest mean follow-up time was 221.7 (SD: 10.9) days post COVID-19 onset. Over 60 physical and psychological signs and symptoms with wide prevalence were reported, most commonly weakness (41%; 95% CI 25% to 59%), general malaise (33%; 95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%) and breathlessness (25%; 95% CI 18% to 34%). 37% (95% CI 18% to 60%) of patients reported reduced quality of life; 26% (10/39) of studies presented evidence of reduced pulmonary function.
CONCLUSION
Long COVID is a complex condition with prolonged heterogeneous symptoms. The nature of studies precludes a precise case definition or risk evaluation. There is an urgent need for prospective, robust, standardised, controlled studies into aetiology, risk factors and biomarkers to characterise long COVID in different at-risk populations and settings.
PROSPERO REGISTRATION NUMBER
CRD42020211131.
Identifiants
pubmed: 34580069
pii: bmjgh-2021-005427
doi: 10.1136/bmjgh-2021-005427
pmc: PMC8478580
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/8
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JSuett declares he is an individual living with long-term symptoms of probably COVID-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.
Références
Clin Microbiol Infect. 2021 Jun;27(6):892-896
pubmed: 33662544
Lung. 2021 Apr;199(2):113-119
pubmed: 33569660
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Arch Bronconeumol. 2021 Apr;57:59-61
pubmed: 34629656
Rhinology. 2021 Feb 1;59(1):26-31
pubmed: 33320115
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18606
pubmed: 32240095
JAMA Netw Open. 2021 Jan 4;4(1):e2036142
pubmed: 33502487
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
J Clin Epidemiol. 2017 Nov;91:23-30
pubmed: 28912002
JAMA. 2006 Feb 8;295(6):676-80
pubmed: 16467236
Lancet. 2021 Feb 6;397(10273):455-457
pubmed: 33357467
Int J Infect Dis. 2021 Mar;104:685-692
pubmed: 33540129
J Clin Epidemiol. 2000 Nov;53(11):1119-29
pubmed: 11106885
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Stat Med. 2017 Nov 10;36(25):3923-3934
pubmed: 28748567
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
J Dent Res. 2021 May;100(5):464-471
pubmed: 33655804
Res Synth Methods. 2019 Sep;10(3):476-483
pubmed: 30945438
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Soc Sci Med. 2021 Jan;268:113426
pubmed: 33199035
F1000Res. 2020 Dec 14;9:1455
pubmed: 34621523
Eur Radiol. 2021 Sep;31(9):7172-7183
pubmed: 33704519
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Brain Behav Immun. 2021 May;94:138-147
pubmed: 33639239
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Eur J Phys Rehabil Med. 2021 Apr;57(2):199-207
pubmed: 33565741
J Ultrasound Med. 2021 Sep;40(9):1823-1838
pubmed: 33185316
Clin Infect Dis. 2021 Dec 16;73(12):2228-2239
pubmed: 33596592
Eur Respir J. 2021 Jul 22;58(1):
pubmed: 33574077
Am J Otolaryngol. 2021 Sep-Oct;42(5):102648
pubmed: 33799139
JAMA Netw Open. 2021 Mar 1;4(3):e211095
pubmed: 33688965
Ann Am Thorac Soc. 2021 Jul;18(7):1253-1255
pubmed: 33472019
J Infect. 2021 Apr;82(4):e31-e33
pubmed: 33373650
J Neurovirol. 2021 Feb;27(1):154-159
pubmed: 33528827
Int J Environ Res Public Health. 2021 Feb 20;18(4):
pubmed: 33672759
Epidemiol Infect. 2021 Jan 19;149:e32
pubmed: 33461632
Clin Microbiol Infect. 2021 Jun;27(6):931-932
pubmed: 33418020
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Radiology. 2021 Apr;299(1):E177-E186
pubmed: 33497317
J Clin Nurs. 2021 Jun;30(11-12):1742-1750
pubmed: 33656210
JACC Cardiovasc Imaging. 2020 Nov;13(11):2330-2339
pubmed: 32763118
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Clin Infect Dis. 2021 Aug 2;73(3):e826-e829
pubmed: 33624010
Lancet Gastroenterol Hepatol. 2021 May;6(5):344-346
pubmed: 33711290
Clin Microbiol Infect. 2021 Feb 16;:
pubmed: 33607252
Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063
pubmed: 33252665
Thromb Res. 2020 Dec;196:454-456
pubmed: 33065410
BMC Health Serv Res. 2020 Dec 20;20(1):1144
pubmed: 33342437
BMJ. 2020 Sep 7;370:m3489
pubmed: 32895219
Eur Respir J. 2021 Sep 16;58(3):
pubmed: 33574080
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
Pan Afr Med J. 2020 Dec 01;37:289
pubmed: 33654513
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Eur J Neurol. 2021 Oct;28(10):3348-3359
pubmed: 33682276